Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q1 2022 · 10-Q
Revenue$117.17M$117.17M+1.4% vs Q1 2021 Net Income-$49.41M-$49.41MN/M vs Q1 2021 EPS Diluted-$0.40-$0.40N/M vs Q1 2021 Gross Profit$38,232,000−8.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Operating Cash Flow-$29,040,000N/M Free Cash Flowderived-$37,259,000N/M Margins · derivedGross margin32.6%−3.4 pt vs Q1 2021
Operating margin-44.4%−31.3 pt vs Q1 2021
Net margin-42.2%−23.0 pt vs Q1 2021
ended Mar 31, 2022 · filed May 9, 2022 · 39 d after period end